Sorafenib loaded pluronic F127-lithocholic acid micelles for prostate cancer therapy: Formulation, optimization, and in vitro evaluation against LNCaP cells
Source abstract
Abstract
In present study, sorafenib loaded nanomicelles were prepared with synthesized pluronic F127 - lithocholic acid by film hydration method. The optimized micelles were spherical showing particle size of 319.36 nm, zeta potential of -11.96 mV, encapsulation efficiency of 87.31%, loading efficiency of 14.87% and release efficiency of 30.1%. Sorafenib loaded nanomicelles showed negligible hemolysis activity on RBC, indicating excellent hemocompatibility of pluronic F127 - lithocholic acid. The drug free nanomicelles showed no cytotoxicity against L929 cells by using MTT assay. However, micellar sorafenib showed more anti-proliferation effect on LNCaP and DU145 cells as compared with free sorafenib.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran;
Department of Medicinal Chemistry, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran;
Department of Pharmaceutical Biotechnology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran;
Drug Design and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran
Funding
Research Vice Chancellery of Isfahan University of Medical Sciences
References (54)
Show source-provided references
1. Armstrong C.-M. · Am J Clin Exp Urol · 2015 · 3 · 64
2. 10.3109/1061186X.2015.108636010.3109/1061186X.2015.1086360 ↗
3. 10.1155/2014/32359410.1155/2014/323594 ↗
4. 10.1056/NEJMoa04072010.1056/NEJMoa040720 ↗
5. 10.1038/sj.bjc.660406410.1038/sj.bjc.6604064 ↗
6. 10.1016/j.powtec.2015.04.04410.1016/j.powtec.2015.04.044 ↗
7. 10.3109/02652048.2011.59061410.3109/02652048.2011.590614 ↗
8. 10.1016/j.ijpharm.2011.08.00310.1016/j.ijpharm.2011.08.003 ↗
9. 10.1016/j.carbpol.2015.09.02310.1016/j.carbpol.2015.09.023 ↗
10. 10.1016/j.nano.2012.05.00910.1016/j.nano.2012.05.009 ↗
11. 10.2174/138945011566614061912570110.2174/1389450115666140619125701 ↗
12. 10.1016/j.jconrel.2011.06.00110.1016/j.jconrel.2011.06.001 ↗
13. 10.1166/jnn.2018.1542010.1166/jnn.2018.15420 ↗
14. 10.1016/S0169-409X(02)00044-310.1016/S0169-409X(02)00044-3 ↗
15. 10.1016/S0168-3659(01)00492-810.1016/S0168-3659(01)00492-8 ↗
16. 10.3109/08982104.2014.96102210.3109/08982104.2014.961022 ↗
17. 10.2147/IJN.S2982710.2147/IJN.S29827 ↗
18. 10.1016/j.biomaterials.2009.11.10210.1016/j.biomaterials.2009.11.102 ↗
19. 10.1016/j.colsurfb.2011.08.01010.1016/j.colsurfb.2011.08.010 ↗
20. 10.1016/j.jconrel.2004.11.01810.1016/j.jconrel.2004.11.018 ↗
21. 10.1016/j.ijpharm.2007.05.03610.1016/j.ijpharm.2007.05.036 ↗
22. Bard J.-M. · FASEB J · 2017 · 31 · 790
23. 10.7717/peerj.12210.7717/peerj.122 ↗
24. 10.1166/jnn.2010.216310.1166/jnn.2010.2163 ↗
25. 10.1002/adhm.20130069110.1002/adhm.201300691 ↗
26. 10.1002/mabi.20140047510.1002/mabi.201400475 ↗
27. 10.1016/j.msec.2016.05.03610.1016/j.msec.2016.05.036 ↗
28. 10.1002/mnfr.20100031010.1002/mnfr.201000310 ↗
29. 10.1080/10717544.2016.122321610.1080/10717544.2016.1223216 ↗
30. 10.1088/0957-4484/20/5/05510610.1088/0957-4484/20/5/055106 ↗
31. 10.1016/S0169-409X(02)00015-710.1016/S0169-409X(02)00015-7 ↗
32. 10.1016/j.ejpb.2006.06.00310.1016/j.ejpb.2006.06.003 ↗
33. 10.1021/la703950910.1021/la7039509 ↗
34. 10.1016/j.carbpol.2008.11.00810.1016/j.carbpol.2008.11.008 ↗
35. 10.1016/j.jconrel.2005.09.03410.1016/j.jconrel.2005.09.034 ↗
36. 10.1016/j.ajps.2014.06.00610.1016/j.ajps.2014.06.006 ↗
37. Liu H. · Int J Nanomedicine · 2015 · 10 · 6395
38. 10.1080/1385772X.2012.68832810.1080/1385772X.2012.688328 ↗
39. 10.1016/j.colsurfb.2008.10.02010.1016/j.colsurfb.2008.10.020 ↗
40. 10.1016/j.ijpharm.2008.08.01110.1016/j.ijpharm.2008.08.011 ↗
41. 10.1016/j.msec.2017.07.04010.1016/j.msec.2017.07.040 ↗
42. 10.1021/ma00056a03510.1021/ma00056a035 ↗
43. 10.1016/j.cej.2013.11.08610.1016/j.cej.2013.11.086 ↗
44. 10.1016/j.carbpol.2011.08.09310.1016/j.carbpol.2011.08.093 ↗
45. 10.1049/iet-nbt.2014.007610.1049/iet-nbt.2014.0076 ↗
46. 10.1016/j.jconrel.2005.09.03910.1016/j.jconrel.2005.09.039 ↗
47. Chen L. · Int J Nanomedicine · 2013 · 8 · 73
48. 10.3109/1071754100372068810.3109/10717541003720688 ↗
49. 10.1080/03639045.2017.139183210.1080/03639045.2017.1391832 ↗
50. 10.1039/C1JM13588K10.1039/C1JM13588K ↗
51. 10.1007/s12274-011-0184-z10.1007/s12274-011-0184-z ↗
52. 10.1007/s11671-009-9427-210.1007/s11671-009-9427-2 ↗
53. 10.1016/j.colsurfb.2008.01.02110.1016/j.colsurfb.2008.01.021 ↗
54. 10.1530/ERC-11-029810.1530/ERC-11-0298 ↗